Soheil Meshinchi, MD, PhD

Soheil Meshinchi, MD, PhD

Cancer and Blood Disorders Center, High-Risk Leukemia Program, Pediatric Blood and Marrow Transplant Program

On staff since September 2000

Academic Title: Professor

Research Center: Center for Clinical and Translational Research

  • Biography

    Soheil Meshinchi, MD, PhD, is attending physician at Seattle Children’s Hospital, associate professor at the University of Washington School of Medicine and associate member of Fred Hutchinson Cancer Research Center (FHCRC). He attends on the Hematopoietic Stem Cell Transplant Service. He is co-director of the COG Myeloid Resource Laboratory, chairman of the COG Myeloid Disease Biology Committee, Vice chair of the COG Myeloid Disease committee and the Biology chair and vice chair of the COG acute myeloid leukemia (AML) phase III trial.

    In addition, he serves on several COG committees, including the committee for development of new APL therapy, phase III AML committee, phase II trial of STI571 for Philadelphia chromosome leukemias and the infant leukemia steering committee. Dr. Meshinchi’s clinical and research interests center around the treatment of pediatric myeloid leukemia. He is principal investigator on ten research projects at FHCRC and Seattle Children’s, including a study on the biology of the alterations of the signal transduction pathway in pediatric cancers, the biology and prognostic implications of FLT3 mutations in AML and the evaluation of minimal residual disease by multiparameter flow cytometry for risk identification. He supervises the treatment and management of all patients with myeloid diseases (AML, MDS, etc.) in the Seattle Cancer Care Alliance, and he is working to identify novel therapies in AML.

    • Related Pages

  • Patient Testimonials

    Be the first to recommend Soheil Meshinchi, MD, PhD

  • Publications

    Other Publications

    • Pulikkan JA, Peramangalam PS, Dengler V, Ho PA, Preudhomme C, Meshinchi S, Christopeit M, Nibourel O, Müller-Tidow C, Bohlander SK, Tenen DG, Behre G
      C/EBP{alpha}-regulated microRNA-34a targets E2F3 during granulopoiesis and is downregulated in AML with CEBPA mutations.
      20889924 Blood, 2010 Oct 1
    • Radhi M, Meshinchi S, Gamis A
      Prognostic factors in pediatric acute myeloid leukemia.
      20652454 Current hematologic malignancy reports, 2010 Oct. : 200-6
    • Pulikkan JA, Peramangalam PS, Dengler V, Ho PA, Preudhomme C, Meshinchi S, Christopeit M, Nibourel O, Müller-Tidow C, Bohlander SK, Tenen DG, Behre G
      C/EBP{alpha}-regulated microRNA-34a targets E2F3 during granulopoiesis and is downregulated in AML with CEBPA mutations.
      20889924 Blood, 2010 Oct 1
    • Radhi M, Meshinchi S, Gamis A
      Prognostic factors in pediatric acute myeloid leukemia.
      20652454 Current hematologic malignancy reports, 2010 Oct. : 200-6
    • Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B, Franklin JL, Lange B, Meshinchi S
      Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
      20413658 Blood, 2010 Aug 5 : 702-10
    • Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B, Franklin JL, Lange B, Meshinchi S
      Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
      20413658 Blood, 2010 Aug 5 : 702-10
    • Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM
      MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.
      20582981 Pediatric blood & cancer, 2010 Aug. : 248-53
    • Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM
      MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.
      20582981 Pediatric blood & cancer, 2010 Aug. : 248-53
    • Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, Meshinchi S, Degar B, Airewele G, Raimondi SC, Onciu M, Coustan-Smith E, Downing JR, Leung W, Pui CH, Campana D
      Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
      20451454 The lancet oncology, 2010 June : 543-52
    • Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, Meshinchi S, Degar B, Airewele G, Raimondi SC, Onciu M, Coustan-Smith E, Downing JR, Leung W, Pui CH, Campana D
      Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
      20451454 The lancet oncology, 2010 June : 543-52
    • Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M, Weinstein HJ, Hirsch B, Raimondi SC, Heerema NA, Woods WG, Lange BJ, Hurwitz C, Arceci RJ, Radich JP, Bernstein ID, Heinrich MC, Meshinchi S
      Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
      20056794 Blood, 2010 Mar 25 : 2372-9
    • Stirewalt DL, Meshinchi S
      Receptor tyrosine kinase alterations in AML - biology and therapy.
      20306247 Cancer treatment and research, 2010 : 85-108
    • Meshinchi S, Appelbaum FR
      Structural and functional alterations of FLT3 in acute myeloid leukemia.
      19549778 Clinical cancer research : an official journal of the American Association for Cancer Research, 2009 Jul 1 : 4263-9
    • Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Franklin JL, Radich JP, Meshinchi S
      Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
      19304957 Blood, 2009 Jun 25 : 6558-66
    • Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM
      Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.
      19036079 British journal of haematology, 2009 Feb. : 388-94
    • Meshinchi S, Stirewalt DL, Alonzo TA, Boggon TJ, Gerbing RB, Rocnik JL, Lange BJ, Gilliland DG, Radich JP
      Structural and numerical variation of FLT3/ITD in pediatric AML.
      18305215 Blood, 2008 May 15 : 4930-3
    • Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, Engel JH, Cronk MR, Dorcy KS, McQuary AR, Hockenbery D, Wood B, Heimfeld S, Radich JP
      Identification of genes with abnormal expression changes in acute myeloid leukemia.
      17910043 Genes, chromosomes & cancer, 2008 Jan. : 8-20
    • Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo N, Dahl G, Alonzo TA, Chang M, Arceci RJ, Small D
      The incidence and clinical significance of nucleophosmin mutations in childhood AML.
      17440048 Blood, 2007 Aug 1 : 979-85
    • Barbaric D, Alonzo TA, Gerbing RB, Meshinchi S, Heerema NA, Barnard DR, Lange BJ, Woods WG, Arceci RJ, Smith FO
      Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961.
      17158236 Blood, 2007 Mar 15 : 2314-21
    • Meshinchi S, Arceci RJ
      Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.
      17405900 The oncologist, 2007 March : 341-55
    • Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, Kaspers GJ, Heerema NA, Gerbing R, Lange BJ, Radich JP
      Clinical implications of FLT3 mutations in pediatric AML.
      16912228 Blood, 2006 Dec 1 : 3654-61
    • Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, Kaspers GJ, Heerema NA, Gerbing R, Lange BJ, Radich JP
      Clinical implications of FLT3 mutations in pediatric AML.
      16912228 Blood, 2006 Dec 1 : 3654-61
    • Pollard JA, Alonzo TA, Gerbing RB, Woods WG, Lange BJ, Sweetser DA, Radich JP, Bernstein ID, Meshinchi S
      FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
      16809615 Blood, 2006 Oct 15 : 2764-9
    • Pollard JA, Alonzo TA, Gerbing RB, Woods WG, Lange BJ, Sweetser DA, Radich JP, Bernstein ID, Meshinchi S
      FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
      16809615 Blood, 2006 Oct 15 : 2764-9
    • Aplenc R, Alonzo TA, Gerbing RB, Smith FO, Meshinchi S, Ross JA, Perentesis J, Woods WG, Lange BJ, Davies SM
      Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group.
      16537811 Blood, 2006 Jul 1 : 74-80
    • Meshinchi S, Arceci RJ, Sanders JE, Smith FO, Woods WB, Radich JP, Alonzo TA
      Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML.
      16790584 Blood, 2006 Jul 1 : 400; author reply 400-1
    • Aplenc R, Alonzo TA, Gerbing RB, Smith FO, Meshinchi S, Ross JA, Perentesis J, Woods WG, Lange BJ, Davies SM
      Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group.
      16537811 Blood, 2006 Jul 1 : 74-80
    • Meshinchi S, Arceci RJ, Sanders JE, Smith FO, Woods WB, Radich JP, Alonzo TA
      Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML.
      16790584 Blood, 2006 Jul 1 : 400; author reply 400-1
    • Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J, Slovak ML, Willman CL, Radich JP
      Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.
      16368883 Blood, 2006 May 1 : 3724-6
    • Tse W, Meshinchi S, Alonzo TA, Stirewalt DL, Gerbing RB, Woods WG, Appelbaum FR, Radich JP
      Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia.
      15217837 Blood, 2004 Nov 15 : 3058-63
    • Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic BI, Dahl GV
      Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes.
      15251987 Blood, 2004 Nov 1 : 2646-54
    • Thomson B, Park JR, Felgenhauer J, Meshinchi S, Holcenberg J, Geyer JR, Avramis V, Douglas JG, Loken MR, Hawkins DS
      Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
      15382275 Pediatric blood & cancer, 2004 Oct. : 571-9
    • Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, Cheng JW, Lee CM, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, Meshinchi S, Le Beau MM, Emanuel PD, Shannon KM
      Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.
      14644997 Blood, 2004 Mar 15 : 2325-31
    • Stirewalt DL, Meshinchi S, Kussick SJ, Sheets KM, Pogosova-Agadjanyan E, Willman CL, Radich JP
      Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
      14984498 British journal of haematology, 2004 Feb. : 481-4
    • Johnston DL, Meshinchi S, Opheim KE, Pallavicini MG, Feusner J, Woods WG, Lange BJ, Radich JP, Bernstein ID
      Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia.
      14617001 British journal of haematology, 2003 Nov. : 431-5
    • Meshinchi S, Smith FO, Arceci RJ
      Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.
      14521808 Current oncology reports, 2003 Nov. : 489-97
    • Meshinchi S, Leisenring WM, Carpenter PA, Woolfrey AE, Sievers EL, Radich JP, Sanders JE
      Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia.
      14652854 Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2003 Nov. : 706-13
    • Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, Podleschny M, Hählen K, Pieters R, Zimmermann M, Reinhardt D, Harbott J, Creutzig U, Kaspers GJ, Griesinger F
      FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
      12816873 Blood, 2003 Oct 1 : 2387-94
    • Meshinchi S, Stirewalt DL, Alonzo TA, Zhang Q, Sweetser DA, Woods WG, Bernstein ID, Arceci RJ, Radich JP
      Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia.
      12702504 Blood, 2003 Aug 15 : 1474-9
    • Stirewalt DL, Meshinchi S, Radich JP
      Molecular targets in acute myelogenous leukemia.
      12490207 Blood reviews, 2003 March : 15-23

Overview

Medical/Professional School

University of Michigan--Ann Arbor, Ann Arbor, MI
Wayne State University School of Medicine, Detroit, MI

Fellowship

University of Washington School of Medicine, Seattle, WA
Wilmer Eye Institute-Johns Hopkins University, Baltimore, MD

Research Description

My clinical and research interests center around the treatment of pediatric myeloid leukemia. I am principal investigator on six research projects at Seattle Children's and Fred Hutchinson Cancer Research Center, including a study on the biology of the alterations of the signal transduction pathway in pediatric cancers, the biology and prognostic implications of FLT3 mutations in AML and the evaluation of minimal residual disease by multiparameter flow cytometry for risk identification.

Research Focus Area

Cancer, Novel Therapeutics, Refractory and recurrent cancer, Sarcomas, Thyroid Cancer